VFA
GBT

Virtus Fund Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Virtus Fund Advisers’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$369K Buy
+9,390
New +$351K ﹤0.01% 380

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus Fund Advisers's GBT Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q4 2017: 9,390 shares worth $369K. The stake represents ﹤0.01% of the portfolio and ranks #380 among its holdings.

157 funds tracked by Wall St. Rank hold GBT as of Q4 2017.

  • Virtus Fund Advisers held 9,390 shares of Global Blood Therapeutics, Inc. worth $369K as of Q4 2017.
  • Global Blood Therapeutics, Inc. was a new Virtus Fund Advisers position in Q4 2017.
  • Global Blood Therapeutics, Inc. made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #380 holding.
  • 157 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.